Related Experiment Videos
A carcinoembryonic antigen-directed immunotoxin built by linking a monoclonal antibody to a hemolytic toxin
A D Avila1, C Mateo de Acosta, A Lage
1Instituto Nacional de Oncología y Radiobiología, MINSAP, Ciudad de la Habana, Cuba.
Abstract:
Hybrid molecules prepared by linking toxins to monoclonal antibodies (MAbs) are cytotoxic to cells bearing the target antigen. The toxin most widely used has been the plant toxin ricin as the toxic component, which inhibits protein synthesis at the ribosome level. Immunotoxins based on membrane-active, hemolytic toxins can be a useful alternative when directed towards antigens which do not mediate internalization, as is the case for most carcinoma antigens. We present an alternative for toxic components using a hemolytic toxin acting at the membrane level, due to its phospholipase activity. The hemolytic toxin (HT), isolated from the sea anemone Stoichactis helianthus, has been conjugated to a MAb directed against carcinoembryonic antigen (CEA), by means of an artificial disulphide bridge. The hybrid alpha CEA-HT exhibits no hemolytic activity unless it is reduced. It is toxic for cells (MDA-MB-134) expressing CEA and not toxic for cells (MDA-MB-231) not bearing CEA. An excess of free antibody reverses toxicity.
Insights
Researchers developed a novel immunotoxin by linking a sea anemone hemolytic toxin (HT) to a monoclonal antibody (MAb) targeting carcinoembryonic antigen (CEA). This hybrid molecule shows targeted toxicity against CEA-expressing cancer cells, offering a new therapeutic strategy.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- Monoclonal antibodies (MAbs) linked to toxins create immunotoxins for targeted cancer therapy.
- Ricin is a common toxin, but alternatives are needed for antigens not mediating internalization.
- Membrane-active toxins offer an alternative for targeting antigens like those on carcinomas.
Purpose of the Study:
- To develop and evaluate a novel immunotoxin using a sea anemone hemolytic toxin (HT) conjugated to a MAb against carcinoembryonic antigen (CEA).
- To assess the targeted cytotoxicity of the CEA-HT immunotoxin against cancer cells.
- To explore the potential of membrane-acting toxins as alternatives in cancer immunotherapy.
Main Methods:
- Conjugation of a hemolytic toxin (HT) from *Stoichactis helianthus* to a MAb targeting CEA via a disulfide bridge.
- Assessment of the hybrid molecule's hemolytic activity upon reduction.
- Evaluation of the immunotoxin's cytotoxicity against CEA-expressing (MDA-MB-134) and CEA-negative (MDA-MB-231) cell lines.
- Investigation of the effect of excess free antibody on toxicity.
Main Results:
- The hybrid CEA-HT molecule demonstrated reduced hemolytic activity until reduction.
- The CEA-HT immunotoxin was specifically toxic to CEA-expressing cells (MDA-MB-134).
- No toxicity was observed in CEA-negative cells (MDA-MB-231).
- Excess free antibody neutralized the immunotoxin's toxicity, confirming target specificity.
Conclusions:
- A novel, targeted immunotoxin (CEA-HT) was successfully developed using a sea anemone hemolytic toxin.
- This immunotoxin exhibits specific cytotoxicity against CEA-expressing cancer cells, highlighting its therapeutic potential.
- Membrane-active toxins represent a viable alternative for immunotoxin development, particularly for targeting antigens not mediating internalization.